Vitrification

Perma-Fix Reports Financial Results and Provides Business Update for the First Quarter of 2024

Retrieved on: 
Thursday, May 9, 2024
Congress, Continuing resolution, PFAS, DOE, Vexatious litigation, EPA, Investment, Weather, Depreciation, Research, Tax, PESI, Operating cost, Loss, Vitrification, Government, GAAP, Ecosystem

ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the first quarter ended March 31, 2024.

Key Points: 
  • ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the first quarter ended March 31, 2024.
  • Mark Duff, President and CEO of the Company, commented, “As previously disclosed, our financial performance in the first quarter of 2024 was impacted by a few temporary headwinds.
  • However, we have seen steady improvement heading into the second quarter and anticipate a strong second half of 2024.
  • Revenue was $13.6 million for the first quarter of 2024 as compared to $20.1 million for the corresponding period of 2023.

Terra CO2 Enters Permitting Stage for High-Performance Cement Extender Plant in Texas, Creating a Near-Term Solution for Increased Production and Carbon Reduction

Retrieved on: 
Thursday, May 9, 2024
ROI, SCM, Construction, Risk, OPUS, Terra, LC3, Research, Carbon footprint, Life, Carbon, Plant, Building material, SCMS, Vitrification, CO2, RMC, Dallas–Fort Worth metroplex, Cement

The plant will produce Terra's OPUS SCMTM (supplementary cementitious material), a high-performance cement extender expected to displace 40-50% of Portland cement (the most common type of cement) when blended.

Key Points: 
  • The plant will produce Terra's OPUS SCMTM (supplementary cementitious material), a high-performance cement extender expected to displace 40-50% of Portland cement (the most common type of cement) when blended.
  • As the construction industry faces increasing regulatory pressure to reduce its carbon footprint, Terra's OPUS SCM offers a solution that addresses environmental concerns and broader industry needs.
  • Terra's solution extends the life and enhances the ROI of established cement plants while meeting the growing demand for cement.
  • Terra is currently testing OPUS ZEROTM, a complete cement replacement that can reduce greenhouse emissions related to concrete production to zero.

Perma-Fix Achieves 36% Year-Over-Year Increase in Revenue to $22.7 Million for the Fourth Quarter of 2023

Retrieved on: 
Wednesday, March 13, 2024
USGS, Vitrification, Tax, PFAS, JV, COVID-19, Research, PESI, Loss, Adjustment, DOD, EPA, Treatment, European, Economy, Investment, Ecosystem, Coronavirus, Depreciation, GAAP, United States Geological Survey, Continuing resolution, Government, DOE, ERC, Video game

Revenue from the Treatment Segment increased by approximately $1.6 million to $10.2 million in the fourth quarter of 2023 from $8.6 million for the corresponding period of 2022.

Key Points: 
  • Revenue from the Treatment Segment increased by approximately $1.6 million to $10.2 million in the fourth quarter of 2023 from $8.6 million for the corresponding period of 2022.
  • Gross profit for the fourth quarter of 2023 was $4.3 million versus $2.0 million for the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was approximately $9,000 versus operating loss of $1.7 million for the fourth quarter of 2022.
  • Revenue from the Treatment Segment increased by approximately $10.1 million to $43.5 million in 2023 from $33.4 million in 2022.

Castle Connolly Names 40 Physicians within The Prelude Network® as 2024 Top Doctors

Retrieved on: 
Tuesday, February 13, 2024
Fertility preservation, IUI, Education, Reproductive medicine, Physician, Dream, IVF, Parent, Pleasure, Castle Connolly Medical, PGT, NYU, Faculty, Prelude, Vitrification, Artificial insemination, NYU Langone Health, Patient, Genetic testing, Nursing

HOUSTON, Feb. 13, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest and fastest-growing network of fertility providers in North America, today celebrates 40 of its physicians across 14 clinics within its expansive network who are named a 2024 Top Doctor by Castle Connolly.

Key Points: 
  • The recognition methodology has been vetted and endorsed by the Castle Connolly Medical Advisory Board .
  • Prelude specialists include innovators in fertility care who have pioneered some of today's most advanced reproductive technologies, including vitrification, fertility preservation, and preimplantation genetic testing (PGT).
  • Dr. Jamie Grifo , Program Director at NYU Langone Fertility and Chief Executive Physician of Inception, was named a 2024 Castle Connolly Top Doctor for the 25th year in a row.
  • "Inception Fertility extends its heartfelt congratulations to our incredible physicians who are so deserving of the Top Doctor recognition," says TJ Farnsworth, Founder and CEO of Inception Fertility.

Perma-Fix Joint Venture Receives Notice of Intent to Award European Waste Treatment Contract Valued at up to EUR 50 Million

Retrieved on: 
Tuesday, November 28, 2023
European Commission, Risk, Joint Research Centre, Radioactive waste, Ecosystem, Civil service commission, LAW, DOE, EPA, LDR, EUR, Vitrification, Overalls, JRC, PESI

Finalization of this award is subject to execution of a contract by the parties and, until executed, may be withdrawn by the contracting authority.

Key Points: 
  • Finalization of this award is subject to execution of a contract by the parties and, until executed, may be withdrawn by the contracting authority.
  • Mark Duff, Chief Executive Officer, stated, “We are honored that the European Commission has selected the Company’s joint venture with Campoverde Srl to support its radioactive waste cleanup mission.
  • This selection follows an extensive evaluation, and I am pleased to report that we met or exceeded all the requirements for this important project.
  • If the variance is granted, DOE announced the waste could be stabilized and disposed of at the nation’s two long-term disposal landfills in Texas and Utah.

Five Ovation-Supported Research Abstracts Presented at ASRM 2023

Retrieved on: 
Wednesday, October 18, 2023
Research, Vitrification, Fertility, Aetna Health Inc. v. Davila, Congress, Health, Poster, IVF, Valencian Community, San Francisco Bay Area, Reproductive medicine, CO, ICSI, Harbor, MD

Nashville, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ovation® Fertility teams presented three poster and two oral presentations at the 2023 ASRM Scientific Congress & Expo, which takes place in New Orleans, Louisiana, October 14-18, 2023.

Key Points: 
  • Nashville, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ovation® Fertility teams presented three poster and two oral presentations at the 2023 ASRM Scientific Congress & Expo, which takes place in New Orleans, Louisiana, October 14-18, 2023.
  • “ASRM is an event that we look forward to and work toward every year because it provides us so many opportunities to learn and share with other experts in reproductive medicine,” says Matthew “Tex” VerMilyea, Ph.D., HCLD/CC, Ovation’s vice president of scientific advancement.
  • “We are very excited to have been invited to showcase many of our latest research findings, produced in collaboration with our physician partners and key suppliers of advanced reproductive technologies, such as artificial intelligence.”
    This year’s Ovation-supported presentations covered advances in intracytoplasmic sperm injection (ICSI), embryo vitrification, and the use of AI in embryo selection.
  • O-1 – CLINICAL EVALUATION OF A MACHINE LEARNING MODEL FOR EMBRYO SELECTION: A DOUBLE-BLINDED RANDOMIZED COMPARATIVE READER STUDY
    (1)Reproductive Science Center of the San Francisco Bay Area, San Ramon, CA, (2)Alife Health, Inc., Cambridge, MA, (3)Alife Health, Inc., (4)Alife Health, Inc., San Francisco, CA, (5)CCRM Fertility, Lone Tree, CO, (6)IVF Florida Reproductive Associates, Margate, FL, (7)Ovation Fertility, Austin, TX
    (1)Ovation Fertility, San Antonio, TX, (2)Life Whisperer Diagnostics Inc (a subsidiary of Presagen), San Francisco, CA, (3)Australian Research Council Centre of Excellence for Nanoscale BioPhotonics, Adelaide, SA, Australia, (4)IVIRMA Global, Valencia, Spain, (5)IVI Foundation - La Fe Health Research Institute, Valencia, Comunidad Valenciana, Spain, (6)IVF Florida Reproductive Associates, Margate, FL, (7)Shady Grove Fertility, Rockville, MD, (8)Presagen and Life Whisperer, Adelaide, SA, Australia, (9)San Francisco Bay Area, Los Gatos, CA
    (1)Alife Health, Inc., San Francisco, CA, (2)Alife Health, Inc., (3)Boston IVF, Waltham, MA, (4)IVF Florida Reproductive Associates, Margate, FL, (5)Ovation Fertility, Austin, TX, (6) Reproductive Science Center of the San Francisco Bay Area, San Ramon, CA

BioTools Innovator Announces Top 19 Life Sciences Companies Named to the 2023 Cohort

Retrieved on: 
Tuesday, June 6, 2023
Professional Services, Health, Health Technology, Start-Up, Research, Science, Biotechnology, Biomedical Advanced Research and Development Authority, Drug development, Therapy, Abraxis BioScience, Johnson & Johnson, Danaher, RCT, Thermo Fisher Scientific, Catalent, Mass spectrometry, AstraZeneca, Standard BioTools, Qiagen, Microfluidics, Becton, Dickinson and Company headquarters, Development, Research Corporation, Mesa, Vitrification, Cell, Growth, BARDA, Black Snow, Pharmaceutical industry, Management, Fine chemical, Mobile phone, Caesarea, Genentech, Agilent Technologies

BioTools Innovator , the first accelerator focused on life science tools and diagnostics to advance cutting-edge research and improve human health, announced today that 19 companies have been selected to participate in its annual program.

Key Points: 
  • BioTools Innovator , the first accelerator focused on life science tools and diagnostics to advance cutting-edge research and improve human health, announced today that 19 companies have been selected to participate in its annual program.
  • The BioTools Innovator Accelerator is a four-month virtual program providing startups with in-depth, customized mentorship and support from senior industry leaders, funding opportunities, and engagement with peers and advisors.
  • From a pool of more than 260 applicants from 31 countries and 34 U.S. states, the top 19 companies were selected to participate in the BioTools Innovator Accelerator.
  • “BioTools Innovator was launched to provide life science entrepreneurs guidance from experienced industry leaders in biotools and diagnostics to help them be successful,” said Kathryn Zavala, managing director of BioTools Innovator.

Top Factors in Choosing a Fertility Clinic are Accuracy & Safe Egg and Embryo Storage Over Cost, Success Rates, Referrals & Doctor Relationship

Retrieved on: 
Friday, April 28, 2023
Knowledge, Friends, Fear, World Health Organization, ART, Infertility, IVF, Transparency, Patient, Fertility, Vitrification, Summary, Environment, Family, TMRW, Social media, Safety, Automation, Egg, Pharmaceutical industry, Nursing, Birth control

NEW YORK, April 28, 2023 /PRNewswire/ -- RESOLVE: The National Infertility Association ("RESOLVE"), a non-profit organization, and TMRW Life Sciences ("TMRW"), a fertility technology company, today released new data from an independent survey conducted by Untold Research – "A Peek Behind the Curtain: Patients' Knowledge, Fears, and Transparency into an Embryo's Journey."

Key Points: 
  • Survey results show that when selecting a fertility clinic, patients prioritize accuracy and safe egg/embryo storage over clinic success rates, cost, location or recommendations from doctors and friends.
  • Despite prioritizing safe embryo transfers and storage, patients admitted they knew little about how best to ensure the safety of their most precious cells.
  • Both rates were well above those given for clinic success rates, relationship with doctor, cost, location, and referrals.
  • The survey results highlight a strong patient desire for safe, automated, and transparent egg and embryo management and storage solutions.

Perma-Fix Reports Financial Results and Provides Business Update for 2022

Retrieved on: 
Thursday, March 23, 2023
Operating cost, ERC, Loss, Hanford Site, Service, Economy, COVID-19, Tax, Paycheck Protection Program, Coronavirus, Generally Accepted Accounting Principles (United States), GAAP, Research, TBI, ROD, DOE, Ministry of Energy, Ecosystem, Sale, Government, EBITDA, PESI, Vitrification, Small business, Medicine, Depreciation, Growth, Weather, Federation, R, Adjustment, Treatment, Cryptocurrency, Video game

ATLANTA, March 23, 2023 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • ATLANTA, March 23, 2023 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.
  • Revenue from the Services Segment was approximately $8.2 million for the fourth quarter of 2022 and 2021.
  • Gross profit for the fourth quarter of 2022 was $2.0 million and $1.3 million for the fourth quarter of 2021.
  • However, work under these projects resumed/increased starting in the second quarter of 2022 and has since reached full operational status.

Olive Fertility Centre Recognized as #1 Canadian Clinic for Superior Outcomes in Egg Freezing

Retrieved on: 
Monday, January 30, 2023
Olive, LOVE, Fertility, Genetic testing, British Engineering Excellence Awards, Environment, Master of Arts, Certification, Birmingham Women's Fertility Centre, Vitrification, ART, American Board of Commissioners for Foreign Missions, Master, Attention, Freezing, Lead, NIPT, DEB, Doctor of Philosophy, IVF, Birth control, Nursing

VANCOUVER , Jan. 30, 2023   /PRNewswire-PRWeb/ -- Olive Fertility Centre is delighted to announce that the Olive Fertility lab has received multiple awards, including top Canadian Clinic for Superior Outcomes in Egg Vitrification Warming 2022 and Masters of ART at this year's LOVE Awards by Donor Egg Bank USA.

Key Points: 
  • Olive Fertility Centre been recognized as the #1 Canadian fertility clinic by the prestigious Donor Bank UCA for superior outcomes in Egg Thawing as well as receiving awards for the outstanding performance of its embryologists and the Olive Fertility lab.
  • VANCOUVER , Jan. 30, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is delighted to announce that the Olive Fertility lab has received multiple awards, including top Canadian Clinic for Superior Outcomes in Egg Vitrification Warming 2022 and Masters of ART at this year's LOVE Awards by Donor Egg Bank USA.
  • The Excellence Awards were designed to recognize superior embryologists who have mastered the highly technical skill of vitrification freezing and warming.
  • We are thrilled to be recognized by DEB USA, one of the largest egg banks in the world, for our outstanding outcomes, the excellence of our lab and egg thawing protocol," says Dr Gary Nakhuda, Co-director Olive Fertility Centre.